CNTB vs. RAPT, ZVRA, KMDA, NBTX, CTNM, TERN, BMEA, ORGO, VRCA, and AMRN
Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include RAPT Therapeutics (RAPT), Zevra Therapeutics (ZVRA), Kamada (KMDA), Nanobiotix (NBTX), Contineum Therapeutics (CTNM), Terns Pharmaceuticals (TERN), Biomea Fusion (BMEA), Organogenesis (ORGO), Verrica Pharmaceuticals (VRCA), and Amarin (AMRN). These companies are all part of the "pharmaceutical preparations" industry.
Connect Biopharma (NASDAQ:CNTB) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
In the previous week, Connect Biopharma had 1 more articles in the media than RAPT Therapeutics. MarketBeat recorded 2 mentions for Connect Biopharma and 1 mentions for RAPT Therapeutics. RAPT Therapeutics' average media sentiment score of 0.43 beat Connect Biopharma's score of 0.30 indicating that RAPT Therapeutics is being referred to more favorably in the news media.
58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 6.6% of RAPT Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Connect Biopharma currently has a consensus price target of $6.50, indicating a potential upside of 263.13%. RAPT Therapeutics has a consensus price target of $24.67, indicating a potential upside of 515.13%. Given RAPT Therapeutics' higher probable upside, analysts plainly believe RAPT Therapeutics is more favorable than Connect Biopharma.
Connect Biopharma's return on equity of 0.00% beat RAPT Therapeutics' return on equity.
RAPT Therapeutics received 72 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 69.57% of users gave Connect Biopharma an outperform vote while only 66.17% of users gave RAPT Therapeutics an outperform vote.
Connect Biopharma has a beta of -0.49, meaning that its stock price is 149% less volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
Connect Biopharma has higher earnings, but lower revenue than RAPT Therapeutics.
Summary
Connect Biopharma and RAPT Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Connect Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Connect Biopharma Competitors List
Related Companies and Tools
